SEC Comment Letter for Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Jul 11, 2018
Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: July 11, 2018 · CIK: 0001604191 · Accession: 0000000000-18-021145
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226065
Letter
July 11, 2018 Johan M. (Thijs) Spoor Chief Executive Officer AzurRx BioPharma, Inc. 760 Parkside Avenue Downstate Biotechnology Incubator, Suite 304 Brooklyn, NY11226 Re:AzurRx BioPharma, Inc. Registration Statement on Form S-3 Filed July 3, 2018 File No. 333-226065 Dear Mr. Spoor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Jessica R. Sudweeks, Esq.
Show Raw Text
July 11, 2018
Johan M. (Thijs) Spoor
Chief Executive Officer
AzurRx BioPharma, Inc.
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, NY11226
Re:AzurRx BioPharma, Inc.
Registration Statement on Form S-3
Filed July 3, 2018
File No. 333-226065
Dear Mr. Spoor:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Jessica R. Sudweeks, Esq.